You are here: Industry Insights > Biocon

News List

SEC asks Biocon to submit safety, mortality data for Itolizumab expresspharma
December 03, 2020
The company claims that approximately 2000 COVID-19 patients used the drug under the emergency use authorisation.
Biocon ranked among top five biotech employers by US-based Science magazine expresspharma
November 02, 2020
Biocon has ranked among the Top 5 Global Biotech Employers for 2020 on the US-based Science magazine’s annual ‘Science Careers Top 20 Employers’ list. Ranked at No. 5 among global pharma and biotech companies in 2020, Biocon has moved up from No. 7 in ...
Biocon appoints Anupam Jindal as its CFO expresspharma
September 24, 2020
Before joining Biocon, Jindal held the position of Group CFO at Sterlite Technologies since 2006.
Biocon Biologics to get Rs 225 cr from Tata Capital Growth Fund for 0.85 per cent equity stake expresspharma
July 31, 2020
Post the completion of this transaction, Biocon will hold 95.25 per cent stake in Biocon Biologics.
Biocon and Voluntis deal to transform insulin biosimilars personalised care through digital therapeutics: GlobalData expresspharma
July 31, 2020
Biocon plans to create a comprehensive digital therapeutics portfolio by extending its Insulia platform to its complete range of insulin products.
Biocon’s itolizumab fails to be part of Covid-19 management protocols pharmaceutical-technology
July 28, 2020
The National Task Force for Covid-19 in India has denied the inclusion of Biocon’s itolizumab in its clinical management protocols for the disease.
Biocon releases Q1FY21 results; Revenue up by 14 per cent at Rs 1,690 Cr expresspharma
July 27, 2020
The company's Research Services business reported flat revenue growth at Rs 422 Crore due to slowdown of operations impacted by the COVID-19 crisis.
Biocon presents key Insights into clinical study that enabled DCGI approval of Itolizumab expresspharma
July 15, 2020
A multi-centric, open label, two-arm randomized pivotal clinical trial was conducted in 30 eligible patients at four hospitals across Mumbai and New Delhi.
Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vial expresspharma
July 14, 2020
Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications, Biocon had earlier said in a regulatory filing.
Biocon’s drug Itolizumab gets approval to treat Covid-19 pharmaceutical-technology
July 14, 2020
Biopharmaceuticals company Biocon has secured approval from the Drugs Controller General of India (DCGI) for its plaque psoriasis drug Itolizumab (ALZUMAb) for emergency use in Covid-19 patients.

Previous page 1 2 3 4 5 6 Next page